Ipamorelin 5mg

Ipamorelin 5mg — Selective GH Secretagogue Research Peptide

Ipamorelin 5mg is a synthetic pentapeptide derived from GHRP-1, engineered to exhibit potent growth hormone (GH) releasing properties with a selectivity profile that distinguishes it from other GH secretagogues in its class. Supplied as a lyophilised powder or gel in a single 5mg vial with a verified purity of ≥99%, this compound is manufactured to the exacting standards required for in-vitro scientific research.

⚠️ Research Use Only. This product is intended exclusively for in-vitro scientific research. It is not approved for human or animal consumption, clinical use, or therapeutic application.

Table of Contents

1. Product Specifications
2. Mechanism of Action
3. Selectivity Profile — ACTH and Cortisol
4. Research Applications
5. Reconstitution and Storage
6. FAQ

Product Specifications

Mechanism of Action

Ipamorelin functions as a growth hormone secretagogue receptor (GHSR) agonist — binding to GHSR in the pituitary gland and hypothalamus to stimulate endogenous GH release. Its GH-releasing potency in both in-vitro and in-vivo models is comparable to GHRP-6, making it one of the more extensively studied synthetic pentapeptides in this class.

The downstream effects of GH stimulation under investigation include elevation of IGF-1 levels, enhancement of bone mineral content and modulation of insulin and muscle tissue response. These mechanistic pathways form the basis for its investigation across longevity, metabolic and musculoskeletal research applications.

Selectivity Profile — ACTH and Cortisol

The most clinically significant finding in ipamorelin research is its remarkable selectivity. Unlike the majority of GH secretagogues — including GHRP-6 and GHRP-2 — ipamorelin does not induce a significant increase in adrenocorticotropic hormone (ACTH) or cortisol levels at GH-stimulating doses.

This selectivity is of substantial research interest. ACTH and cortisol elevation associated with other GH secretagogues represents a confounding variable in research protocols and a source of physiological side effects in therapeutic contexts. Ipamorelin’s ability to stimulate GH release without triggering this adrenal axis response makes it a uniquely clean research tool for isolating GH-specific effects.

Research Applications

Ipamorelin is investigated across a broad range of research domains consistent with its GH secretagogue profile:

• GH secretagogue selectivity and receptor binding studies
• IGF-1 axis modulation and downstream signalling research
• Bone mineral density and skeletal tissue investigations
• Muscle tissue hypertrophy and IGF-1 mediated growth studies
• Metabolic rate and body composition research
• Sleep architecture and GH pulse correlation studies
• Cellular repair and tissue regeneration investigations

Reconstitution and Storage

Reconstitute with NaCl, sterile water or bacteriostatic water at 1ml per vial. Add solvent slowly along the vial wall and allow to dissolve by gentle rotation. Do not shake or vortex.

Store lyophilised material at −20°C. Once reconstituted, maintain at 4°C and use within the recommended timeframe for your research protocol. Protect from light and avoid repeated freeze-thaw cycles.

Explore additional research peptides in our Longevity and Anti-Age, Muscle Growth and Sleep Enhancement research categories.

FAQ

What is ipamorelin 5mg? Ipamorelin 5mg is a synthetic pentapeptide GH secretagogue derived from GHRP-1. It stimulates endogenous growth hormone release through GHSR agonism with potency comparable to GHRP-6 in both in-vitro and in-vivo models. Its defining characteristic is its selectivity — unlike most GH secretagogues it does not significantly elevate ACTH or cortisol levels. Supplied as a lyophilised powder with ≥99% purity for in-vitro scientific research.

How to reconstitute CJC-1295 ipamorelin 5mg? How to reconstitute CJC-1295 ipamorelin 5mg for in-vitro research: add 1ml of NaCl, sterile water or bacteriostatic water per vial, introducing solvent slowly along the vial wall. Allow the powder to dissolve by gentle rotation — do not shake or vortex. Store the reconstituted solution at 4°C and protect from light. Follow your institutional research protocol for handling and storage timeframes.

What is CJC 1295/ipamorelin blend 5/5mg dosage in research? CJC 1295/ipamorelin blend 5/5mg dosage as studied in published research typically involves combining a GHRH analogue with a GHSR agonist to achieve synergistic GH axis stimulation — the two compounds acting on complementary receptors. Research parameters vary by study design and institutional protocol. Both compounds in this combination are for in-vitro research use only — no therapeutic or personal dosage recommendation is made or implied.

What makes ipamorelin different from other GH secretagogues? The primary distinction is selectivity. Most GH secretagogues — including GHRP-6 — stimulate the release of ACTH and cortisol alongside GH. Ipamorelin does not produce significant ACTH or cortisol elevation at GH-stimulating doses. This selectivity makes it a particularly valuable research tool for isolating GH-specific physiological responses without adrenal axis confounding variables.

What research applications is ipamorelin 5mg used for? Ipamorelin 5mg is used in in-vitro research examining GH secretagogue receptor binding, IGF-1 axis modulation, bone mineral density, skeletal muscle tissue response, metabolic rate investigation, sleep architecture correlation and cellular repair mechanisms. All applications are within approved in-vitro and preclinical research frameworks. This product is not approved for human administration.